Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma

BACKGROUND: Pre-clinically, phosphoinositide 3-kinase (PI3K) inhibition radiosensitises tumours by increasing intrinsic radiosensitivity and by reducing tumour hypoxia. We assessed whether buparlisib, a class 1 PI3K inhibitor, can be safely combined with radiotherapy in patients with non-small cell...

Descripción completa

Detalles Bibliográficos
Autores principales: McGowan, Daniel R., Skwarski, Michael, Bradley, Kevin M., Campo, Leticia, Fenwick, John D., Gleeson, Fergus V., Green, Marcus, Horne, Amanda, Maughan, Timothy S., McCole, Mark G., Mohammed, Seid, Muschel, Ruth J., Ng, Stasya M., Panakis, Niki, Prevo, Remko, Strauss, Victoria Y., Stuart, Robert, Tacconi, Eliana M.C., Vallis, Katherine A., McKenna, W. Gillies, Macpherson, Ruth E., Higgins, Geoff S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522060/
https://www.ncbi.nlm.nih.gov/pubmed/30991262
http://dx.doi.org/10.1016/j.ejca.2019.03.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522060/
https://www.ncbi.nlm.nih.gov/pubmed/30991262
http://dx.doi.org/10.1016/j.ejca.2019.03.015

Ejemplares similares